Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / articles / BMY - Bristol Myers Squibb Announces Phase 3 Results Of Opdivo/Yervoy Combo In Liver Cancer Patients | Benzinga

BMY - Bristol Myers Squibb Announces Phase 3 Results Of Opdivo/Yervoy Combo In Liver Cancer Patients | Benzinga

Bristol-Myers Squibb Company

Bristol Myers Squibb Co (NYSE:BMY) announced on Tuesday the first presentation of results from the Phase 3 CheckMate -9DW trial evaluating the dual immunotherapy combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to lenvatinib or sorafenib for unresectable hepatocellular carcinoma (HCC).

Related: FDA Expands Approval For Bristol Myers Squibb’s Breyanzi, Making CAR T Cell Therapy Available For Broadest Range Of B-Cell Malignancies.

With a median follow-up ...

Full story available on Benzinga.com
Stock Information
Company Name: Bristol-Myers Squibb Company
Stock Symbol: BMY
Market: NYSE
Website: bms.com
Menu
BMY BMY Quote BMY Short BMY News BMY Articles BMY Message Board
Get BMY Alerts

News, Short Squeeze, Breakout and More Instantly...